ASCO GU 2018: The CLEAR study: A Phase 3 Trial to Compare Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-line Treatment of Patients with Metastatic Renal Cell Carcinoma
San Francisco, CA (UroToday.com) Lenvatinib (LEN) is a multikinase inhibitor of vascular endothelial growth factor (VEGF) receptor 1–3, fibroblast growth factor receptor 1–4, platelet-derived growth factor receptor alpha, and RET and KIT. Based on a phase 2 study,1 LEN was approved in combination with everolimus (EVE) for the treatment of metastatic renal cell carcinoma (RCC) following 1 prior VEGF-targeted therapy. A phase 1b/2 study of LEN in combination with pembrolizumab (PEM) in patients (pts) with RCC is also underway.
ASCO GU 2018: Self-reported Quality of Life as a Predictor of Survival in Renal Cell Carcinoma
San Francisco, CA (UroToday.com) While biomarkers for various malignancies continue to be developed, sometimes there can be no substitute for a physical and mental exam. Clinical evaluation of the patient may provide guidance into their cancer-related status and perhaps even serve as a biomarker.
ASCO GU 2018: Treatment Facility Volume and Survival in Patients with metastatic Renal Cell Carcinoma
San Francisco, CA (UroToday.com) Prognosis of metastatic renal cell carcinoma (mRCC) has significantly improved in the targeted therapy era. Novel therapies continue to be developed for mRCC, making the management much more nuanced.
ASCO GU 2018: Carcinomas of the Renal Medulla: A Comprehensive Genomic Profiling Study
San Francisco, CA (UroToday.com) Collecting duct carcinoma (CDC) and renal medullary carcinoma (RMC) represent rare renal tumors that arise in the renal medulla, resistant to therapy, and progress rapidly.
ASCO GU 2018: Association of Dividing Pathologically Upstaged T3a Renal Cell Carcinoma with Improved Alignment of Outcomes: A Call for TMN Revision
San Francisco, CA (UroToday.com) Incidental pathological upstaging to pT3a disease can occur after surgical treatment of clinical T1 and T2 Renal Cell Carcinoma (RCC), and upstaged pT3a disease is associated with worsened outcomes. Oncologic and survival outcomes within the pT3a category are heterogeneous. The authors investigated recurrence and survival outcomes in pT3a disease, and aimed to better categorize this cohort for improvement on current TMN staging.
ASCO GU 2018: A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy
San Francisco, CA (UroToday.com) The anti-PD-1 antibody nivolumab (nivo) improves overall survival (OS) in metastatic treatment refractory RCC and is generally tolerable. In 2017, there is no standard adjuvant therapy proven to increase OS over surgery alone in non-metastatic (M0) disease. Mouse solid tumor models have revealed an OS benefit with a short course of neoadjuvant PD-1 blockade compared to adjuvant therapy.
ASCO GU 2018: Treatment trends of localized renal cell carcinoma by hospital type: A NCDB analysis
San Francisco, CA (UroToday.com) Accounting for operative, oncologic and comorbid risks guide treatment recommendations for localized kidney cancers. The authors hypothesized that individualized surgical decision making may also be influenced by surgical center and volume.